Return to search results
Nilotinib
Nilotinib is a prescription oral capsule medication used to treat certain types of leukemia, such as chronic myeloid leukemia. It works as a kinase inhibitor, targeting specific enzymes involved in cancer cell growth. Available in 50mg, 150mg, and 200mg strengths, it is manufactured by Apotex Corp. under application ANDA203640. This information was generated using AI and is provided for informational and research purposes only.
Complete Metadata
| @type | dcat:Dataset |
|---|---|
| accessLevel | public |
| accrualPeriodicity | R/P1Y |
| bureauCode |
[
"009:10"
]
|
| contactPoint |
{
"fn": "Division of Drug Information",
"@type": "vcard:Contact",
"hasEmail": "mailto:druginfo@fda.hhs.gov"
}
|
| description | Nilotinib is a prescription oral capsule medication used to treat certain types of leukemia, such as chronic myeloid leukemia. It works as a kinase inhibitor, targeting specific enzymes involved in cancer cell growth. Available in 50mg, 150mg, and 200mg strengths, it is manufactured by Apotex Corp. under application ANDA203640. This information was generated using AI and is provided for informational and research purposes only. |
| distribution |
[
{
"@type": "dcat:Distribution",
"title": "Nilotinib",
"mediaType": "text/html",
"description": "
Access the FDA dataset for Nilotinib — ANDA 022068 submitted by Mylan Institutional LLC
",
"downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022068"
}
]
|
| identifier | ANDA022068 |
| issued | 2016-09-16 |
| keyword |
[
"drug",
"health-care",
"pharmaceuticals",
"prescription-drugs",
"public-health"
]
|
| landingPage | https://www.fda.gov/drugs |
| license | https://open.fda.gov/license |
| modified | 2025-03-17 |
| programCode |
[
"009:002"
]
|
| publisher |
{
"name": "U.S. Food and Drug Administration",
"@type": "org:Organization"
}
|
| theme |
[
"FDA"
]
|
| title | Nilotinib |
